Enfusion Announces Closing of Initial Public Offering and Full Exercise of Underwriters� Option to Purchase Additional Shares

NEW YORK & LONDON & HONG KONG–(BUSINESS WIRE)–Enfusion, Inc. (“Enfusion”), a leading provider of cloud-based investment management software and services, today announced the closing of its initial public offering of 21,562,500 shares of Class A common stock, including the exercise in full of the underwriters� option to purchase up to an additional 2,812,500 shares, at a price of $17.00 per share. The offering comprised the sale of 16,839,107 shares of Class A common stock offered by Enfusion and 4,723,393 shares of Class A common stock sold by certain of Enfusion’s stockholders. The shares began trading on the New York Stock Exchange on October 21, 2021 under the ticker symbol “ENFN”.

Enfusion intends to use the net proceeds received from the offering to purchase equity interests in its operating subsidiary Enfusion Ltd. LLC from certain of Enfusion’s pre-IPO equity holders and to purchase newly-issued equity interests in Enfusion Ltd. LLC. In turn, Enfusion Ltd. LLC intends to apply the balance of the net proceeds it receives from Enfusion to repay indebtedness, pay expenses incurred in connection with the IPO and the other organizational transactions contemplated thereby and for general corporate purposes.

Morgan Stanley & Co. LLC and Goldman Sachs & Co. LLC acted as lead book-running managers for the proposed offering, with BofA Securities, Credit Suisse Securities (USA) LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C. acting as additional bookrunners, and Loop Capital Markets LLC acting as co-manager.

The offering was made only by means of a prospectus, copies of which may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, New York 10014, Attn: Prospectus Department, by email: prospectus@morganstanley.com; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ny.email.gs.com.

A registration statement relating to this offering was declared effective by the Securities and Exchange Commission on October 20, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Enfusion

Enfusion’s investment management software-as-a-service platform removes traditional information boundaries, uniting front-, middle- and back-office teams on one cloud-native system. Through its software, analytics, and middle/back-office managed services, Enfusion creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility, and powering growth. Enfusion partners with 600+ investment managers from nine global offices spanning four continents.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including regarding the use of proceeds from Enfusion’s initial public offering. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as “outlook,” “believe(s),” “expect(s),” “potential,” “continue(s),” “may,” “will,” “should,” “could,” “would,” “seek(s),” “predict(s),” “intend(s),” “trends,” “plan(s),” “estimate(s),” “anticipates,” “projection,” “will likely result” and or the negative version of these words or other comparable words of a future or forward-looking nature. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. These factors include but are not limited to those described under “Risk Factors” in Enfusion’s registration statement relating to the initial public offering. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in the registration statement. Enfusion undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

Contacts

Media:
Prosek Partners

pro-enfusion@prosek.com

Investor Relations:
ICR

Brian Murphy

brian.murphy@icrinc.com